Daily Respiratory Research Analysis
Analyzed 67 papers and selected 3 impactful papers.
Summary
Three papers stood out today: a Cell study demonstrating that ferroptosis inhibition preserves liver and lung grafts in ex vivo perfusion, a multicenter prospective study establishing quantitative interpretation models for targeted NGS in lower respiratory tract infections, and a meta-analysis of randomized trials showing clinical benefits of high-dose quadrivalent influenza vaccine in older adults. Together, they advance transplantation science, infectious diagnostics, and respiratory prevention.
Research Themes
- Ferroptosis inhibition to improve organ transplantation outcomes
- Quantitative genomics for pathogen detection in lower respiratory tract infections
- Vaccine dose optimization to reduce cardio-respiratory hospitalizations in older adults
Selected Articles
1. Ferroptosis inhibition enhances liver and lung graft function.
This translational study identifies early lipid peroxidation during human liver transplantation and demonstrates that ferroptosis inhibitors (FXT-001) preserve porcine liver and lung grafts and sustain viability of declined human lungs during split ex vivo perfusion. Second-generation compounds (FXT-002/003) improved PK and safety, positioning ferroptosis blockade as a druggable axis for ischemia–reperfusion injury in transplantation.
Impact: Provides mechanistic validation and multi-species evidence, including declined human lungs, that ferroptosis is a modifiable driver of graft failure. Opens a plausible translational pathway for organ preservation and expansion of donor pools.
Clinical Implications: Ferroptosis inhibitors could be incorporated into ex vivo lung perfusion and liver perfusion protocols to reduce ischemia–reperfusion injury, potentially improving utilization and early function of marginal grafts. Early-phase clinical trials in EVLP/EVLP-like platforms are warranted.
Key Findings
- Early, transient lipid peroxidation was detected in human liver transplants and validated as a target.
- FXT-001 protected porcine liver and lung grafts during ex situ perfusion.
- In split ex vivo perfusion of declined human lungs, FXT-001 preserved graft viability whereas controls deteriorated.
- Next-generation inhibitors (FXT-002/FXT-003) with improved PK/safety were developed.
Methodological Strengths
- Translational pipeline across human tissue, porcine organ ex situ perfusion, and declined human donor lungs
- Mechanistic targeting of lipid peroxidation with defined ferroptosis inhibitors and assessment of graft viability/function
Limitations
- Preclinical study without randomized clinical outcomes
- Sample sizes for declined human lung split-perfusion experiments are not reported and likely small
Future Directions: Conduct phase 1/2 trials integrating ferroptosis inhibitors into EVLP/ELVP protocols, define dose-exposure-response in human grafts, and assess early post-transplant outcomes including PGD and ICU metrics.
Ischemia-reperfusion injury (IRI) is a major clinical challenge in transplantation, vascular surgeries, myocardial infarction, and stroke. Disruption of energy and redox homeostasis triggers ferroptosis, a regulated, iron-dependent form of cell death, leading to organ dysfunction. We identify an early and transient increase of lipid peroxidation in human liver transplants and validate it as a therapeutic target. FXT-001, a ferroptosis inhibitor with dual radical and iron-trapping activity, provides robust protection in preclinical models, including ex situ perfusion of porcine liver and lung grafts. In a split ex vivo machine perfusion setting using declined human donors, FXT-001 treatment preserves graft viability, whereas untreated lungs deteriorate. We also develop FXT-002 and FXT-003 with enhanced pharmacokinetic and safety profiles. These findings support the use of ferroptosis inhibitors as a therapeutic strategy in transplantation and other IRI-associated conditions.
2. ZDHHC18-Mediated Palmitoylation of ORF3a Promotes SARS-CoV-2 Pathogenesis by Antagonizing TRIM16-Mediated Ubiquitination and Proteasomal Degradation.
The study identifies ZDHHC18-mediated palmitoylation of ORF3a at Cys130/Cys133 as a key stabilizing modification that blocks TRIM16-mediated K27-linked ubiquitination, enhancing viral replication and inflammation. An ORF3a-mimicking peptide (OPIP) disrupted palmitoylation, accelerated ORF3a degradation, and reduced SARS-CoV-2 pathogenicity, nominating a druggable ORF3a–ZDHHC18–TRIM16 axis.
Impact: Reveals a previously uncharacterized, druggable post-translational control of a key SARS-CoV-2 accessory protein with an inhibitory peptide prototype, bridging mechanistic insight to therapeutic concept.
Clinical Implications: Targeting palmitoylation (e.g., ZDHHC18 or ORF3a–enzyme interaction) could complement current antivirals by destabilizing virulence factors; peptide or small-molecule inhibitors warrant preclinical development and safety evaluation.
Key Findings
- ORF3a is palmitoylated by ZDHHC18 at conserved Cys130/Cys133, stabilizing the protein.
- Palmitoylation prevents TRIM16-dependent K27-linked polyubiquitination and proteasomal degradation.
- An ORF3a-mimicking palmitoylation-inhibitory peptide (OPIP) reduces palmitoylation, promotes degradation, and attenuates SARS-CoV-2 pathogenicity.
Methodological Strengths
- Multi-level mechanistic dissection (PTM mapping, E3 ligase competition, stability assays) with functional readouts of replication and inflammation
- Therapeutic prototype (OPIP) demonstrating target engagement and phenotypic rescue
Limitations
- Predominantly preclinical cellular/biochemical assays; in vivo efficacy and safety remain to be established
- Potential viral strain/variant-specific differences in ORF3a regulation not fully addressed
Future Directions: Advance OPIP analogs and small-molecule palmitoylation inhibitors into in vivo models, define resistance liabilities across variants, and evaluate combination with approved antivirals.
SARS-CoV-2 accessory protein ORF3a contributes to viral pathogenesis through membrane remodeling, immune evasion, and inflammation induction. However, the molecular mechanisms underlying ORF3a-mediated pathogenesis remain poorly characterized, and no therapeutic strategies targeting ORF3a currently exist. Here, we demonstrate that palmitoylation, a post-translational modification, governs ORF3a-mediated viral pathogenesis. Specifically, ORF3a undergoes ZDHHC18-mediated palmitoylation at evolutionarily conserved Cys130/Cys133 residues, which stabilizes the protein by masking an intrinsic proteasomal degradation signal. This palmitoylation competitively inhibits tripartite motif-containing 16 (TRIM16)-dependent K27-linked polyubiquitination, thereby preventing ORF3a degradation and enhancing viral replication and inflammatory responses. A designed ORF3a-mimicking palmitoylation-inhibitory peptide (OPIP) blocked ORF3a palmitoylation, promoted its degradation, and significantly reduced SARS-CoV-2 pathogenicity. Collectively, these findings establish ZDHHC18-mediated palmitoylation as a central regulator of ORF3a stability and virulence, revealing a potentially druggable axis for disrupting SARS-CoV-2 pathogenesis.
3. Quantitative interpretation models for targeted next-generation sequencing in lower respiratory tract infections: a multicenter prospective study.
In 631 ICU patients with suspected LRTIs, quantitative tNGS models using RPKM and copy-number thresholds outperformed conventional microbiology and qualitative tNGS, achieving 82.4% sensitivity and 85.0% specificity. The approach improved discrimination of true pathogens from background and showed high concordance for key AMR determinants.
Impact: Establishes validated, quantitative interpretation criteria for tNGS in LRTIs, a key translational barrier to clinical deployment of sequencing-based diagnostics.
Clinical Implications: Quantitative tNGS thresholds can be integrated into ICU diagnostic workflows to improve pathogen calling in BALF, aid antimicrobial selection, and refine AMR risk assessment.
Key Findings
- Quantitative models (RPKM and copy number) achieved sensitivity 82.4% and specificity 85.0%, outperforming conventional tests and qualitative tNGS.
- tNGS enhanced detection of Gram-negative bacteria, Candida spp., and Pneumocystis jirovecii, while conventional tests better detected Aspergillus.
- High concordance for key AMR markers (KPC, NDM, OXA-48, mecA) with moderate overall AMR prediction (AUC 0.715).
Methodological Strengths
- Prospective multicenter design with independent training (n=420) and validation (n=211) cohorts
- Blinded expert adjudication across three panels to define reference standards and avoid quantitative bias
Limitations
- Aspergillus detection remained inferior with tNGS versus conventional methods
- Study conducted in five ICUs in eastern China; external generalizability requires broader validation
Future Directions: Calibrate models for fungi (e.g., Aspergillus), integrate host-response markers, and test clinical impact in randomized diagnostic stewardship trials.
BACKGROUND: Lower respiratory tract infections (LRTIs) represent a significant global health burden. While targeted next-generation sequencing (tNGS) offers potential advantages for pathogen detection, its clinical implementation is hindered by the absence of validated quantitative interpretation criteria for pathogen discrimination. METHODS: We conducted a multicenter prospective study of 631 patients with suspected LRTIs across five intensive care units in eastern China from January 2022 to March 2025. Bronchoalveolar lavage fluid specimens underwent concurrent tNGS and conventional microbiological testing (CMT). Expert group A established the reference standard by classifying patients into LRTI/non-LRTI categories and identifying clinically significant pathogens based on comprehensive clinical criteria. Expert group B, blinded to tNGS quantitative data, provided qualitative interpretation based solely on detected microorganisms to eliminate any influence from quantitative parameters. Expert group C, blinded to all tNGS data, provided interpretation based on conventional microbiological testing combined with clinical manifestations. Quantitative diagnostic models incorporating reads per kilobase per million mapped reads (RPKM) and pathogen copy numbers were developed using a training cohort (n = 420) and validated in an independent cohort (n = 211). RESULTS: Of 631 patients, 358 (56.7%) met the diagnostic criteria for LRTI. Polymicrobial infections were identified in 77 patients, with the majority co-infected with Acinetobacter baumannii and Pseudomonas aeruginosa. tNGS demonstrated enhanced detection of Gram-negative bacteria, Candida species and Pneumocystis jirovecii, while CMT showed better detection for Aspergillus species. The quantitative models demonstrated excellent discriminatory performance for bacterial pathogens. The sensitivity and specificity for conventional microbiological testing alone were 58.7% and 74.7%. Adding clinical manifestations to CMT resulted in a sensitivity of 68.8% and specificity of 72.0%. In comparison, qualitative tNGS achieved a sensitivity of 78.5% and a specificity of 76.6%, while the model-based algorithm demonstrated the highest diagnostic accuracy with a sensitivity of 82.4% and a specificity of 85.0%. For antimicrobial resistance prediction, tNGS achieved moderate accuracy (AUC 0.715) with high concordance for key antimicrobial resistance markers including KPC, NDM, OXA-48 and mecA. CONCLUSION: We developed and validated quantitative models for tNGS-based pathogen detection in LRTIs, enabling precise discrimination between pathogenic and background organisms. These models represent a significant step forward in the clinical application of tNGS for LRTI diagnosis and antimicrobial resistance detection.